Skip to main content

Table 2 Factors associated with survival outcomes in patients with uterine corpus endometrial carcinoma

From: LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data

Characteristics Overall survival Progression-free survival
N Univariate analysis Multivariate analysis N Univariate analysis Multivariate analysis
HR 95% CI P Adjusted HR 95% CI P HR 95% CI P Adjusted HR 95% CI P
Age, years
 ≥ 63 193 1.456 0.754–2.813 0.263 1.234 0.592–2.570 0.575 157 1.285 0.751–2.197 0.360 1.224 0.676–2.216 0.504
 < 63 177 1 (Ref) 1 (Ref) 177 1 (Ref) 1 (Ref)
Histologic type
 Non-endometrioid 66 2.232 1.146–4.348 0.018 0.887 0.379–2.074 0.782 57 1.987 1.112–3.551 0.020 1.080 0.478–2.442 0.853
 Endometrioid 304 1 (Ref) 1 (Ref) 277 1 (Ref) 1 (Ref)
Grade
 G3 176 3.411 1.661–7.004 0.001 2.016 0.874–4.650 0.100 150 1.539 0.909–2.607 0.109 0.884 0.453–1.724 0.717
 G1,2 194 1 (Ref) 1 (Ref) 184 1 (Ref) 1 (Ref)
FIGO stage
 III-IV 89 4.703 2.474–8.943 < 0.001 3.509 1.734–7.101 < 0.001 72 3.704 2.176–6.307 < 0.001 3.581 1.981–6.473 < 0.001
 I-II 278 1 (Ref) 1 (Ref) 259 1 (Ref) 1 (Ref)
LYL1 amplification
 Yes 22 3.096 1.201–7.982 0.019 1.581 0.541–4.620 0.402 18 2.469 1.055–5.780 0.037 1.652 0.633–4.317 0.305
 No 348 1 (Ref) 1 (Ref) 316 1 (Ref) 1 (Ref)
  1. Abbreviations: HR hazard ratio, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics